Literature DB >> 10071309

Mucocutaneous reactions to chemotherapy.

W S Susser1, D L Whitaker-Worth, J M Grant-Kels.   

Abstract

UNLABELLED: Chemotherapeutic agents are a widely used treatment modality. Side effects range from common to unusual and may be confused with other cutaneous sequelae of oncologic treatment. The goal of this communication is to elaborate on previous descriptions of the cutaneous manifestations of chemotherapeutic treatment and to discuss more recent findings. LEARNING
OBJECTIVE: At the conclusion of this learning activity, participants should be able to generate a differential diagnosis of possible etiologies for varying patterns of cutaneous involvement in patients receiving chemotherapy and identify the various cutaneous side effects of chemotherapeutic treatment. In addition, they should be able to distinguish life-threatening side effects that require immediate management from more benign manifestations of chemotherapeutic treatment.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10071309     DOI: 10.1016/s0190-9622(99)70488-3

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  41 in total

Review 1.  Cutaneous manifestations of cancer and chemotherapy.

Authors:  Emma Topham
Journal:  Clin Med (Lond)       Date:  2009-08       Impact factor: 2.659

2.  Docetaxel Facilitates Endothelial Dysfunction through Oxidative Stress via Modulation of Protein Kinase C Beta: The Protective Effects of Sotrastaurin.

Authors:  Ching-Hsia Hung; Shih-Hung Chan; Pei-Ming Chu; Kun-Ling Tsai
Journal:  Toxicol Sci       Date:  2015-01-28       Impact factor: 4.849

3.  Sorafenib (Nexavar®, BAY 43-9006)-induced Hand-foot Skin Reaction with Facial Erythema.

Authors:  Dong Ha Kim; In Pyeong Son; Jin Woong Lee; Hye In Lee; Beom Joon Kim; Myeung Nam Kim
Journal:  Ann Dermatol       Date:  2011-02-28       Impact factor: 1.444

4.  Case report of cold-weather-induced radiation recall dermatitis after chemoradiotherapy with cisplatin.

Authors:  Isabelle Kindts; Karin Stellamans; Michiel Bonny; Nikie Planckaert; Laurence Goethals
Journal:  Strahlenther Onkol       Date:  2014-04-04       Impact factor: 3.621

Review 5.  Dermatological adverse events with taxane chemotherapy.

Authors:  Vincent Sibaud; Nicole R Lebœuf; Henri Roche; Viswanath R Belum; Laurence Gladieff; Marion Deslandres; Marion Montastruc; Audrey Eche; Emmanuelle Vigarios; Florence Dalenc; Mario E Lacouture
Journal:  Eur J Dermatol       Date:  2016-10-01       Impact factor: 3.328

Review 6.  Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch.

Authors:  Brian A Baldo; Nghia H Pham
Journal:  Cancer Metastasis Rev       Date:  2013-12       Impact factor: 9.264

7.  Unusual nail pigmentation following cyclophosphamide-containing chemotherapy regimen.

Authors:  Santosh Kumar; Rakesh Dixit; Saurabh Karmakar; Sayan Paul
Journal:  Indian J Pharmacol       Date:  2010-08       Impact factor: 1.200

Review 8.  Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG).

Authors:  Christopher J Anker; Kenneth F Grossmann; Michael B Atkins; Gita Suneja; Ahmad A Tarhini; John M Kirkwood
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-06-01       Impact factor: 7.038

9.  Inflammation of actinic keratosis with combination of alkylating and taxane agents: a case report.

Authors:  Fadi Makdsi; Roger Deversa
Journal:  Cases J       Date:  2009-07-02

10.  Anthracycline extravasation injuries: management with dexrazoxane.

Authors:  Karin Jordan; Timo Behlendorf; Franziska Mueller; Hans-Joachim Schmoll
Journal:  Ther Clin Risk Manag       Date:  2009-05-20       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.